secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001193125-25-158192
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics receives FDA clinical hold on LTI-03 Phase 2 trial; cites insufficient nonclinical safety data
--------------------------------------------------------------------------------

- FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.
- FDA cited no NOAEL and minimal mucus cell hyperplasia in 26-week rat study; requests new inhalation toxicity study.
- Company believes existing data supports safety, plans to work with FDA to resolve hold expeditiously.
- Board approved bylaw amendment lowering quorum requirement to 40% of shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/0001193125-25-158192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/d83413d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-158192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer